| Current Price | $67.27 | Mkt Cap | $6.7B |
|---|---|---|---|
| Open | $66.43 | P/E Ratio | 92.89 |
| Prev. Close | $65.53 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $65.70 - $69.00 | Volume | 1,966,633 |
| 52-Wk Range | $11.67 - $73.72 | Avg. Daily Vol. | 2,184,851 |
A development stage nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy.
| Current Price | $67.27 | Mkt Cap | $6.7B |
|---|---|---|---|
| Open | $66.43 | P/E Ratio | 92.89 |
| Prev. Close | $65.53 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $65.70 - $69.00 | Volume | 1,966,633 |
| 52-Wk Range | $11.67 - $73.72 | Avg. Daily Vol. | 2,184,851 |
The best Bull and Bear pitches based on recency and number of recommendations.
Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade,MarketWatch•September 6, 2018MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday,… More
“Arrow - Heading” downward.Arrowhead Research Corporation (Arrowhead) is a development stage nanotechnology company, commercializing technologies in the areas of life sciences, electronics and energy. Arrowhead operates four majority-owned… More
Read the most recent pitches from players about ARWR.
Recs
Bigsef77
(69.72)
Submitted: 9/6/2018 11:23:29 AM :
Start Price:
$1.52
NASDAQ:ARWR Score:
+4,293.92
Arrowhead Pharmaceuticals stock rockets 30% after upbeat trial data prompts analyst upgrade
,MarketWatch•September 6, 2018
MARKET PULSE Shares of Arrowhead Pharmaceuticals Corp. (arwr) rocketed 30% toward a 4 1/2-year high in premarket trade Thursday, after upbeat results of the company's treatment for chronic hepatitis B prompted an upgrade at B.
Recs
Quickcard
(< 20)
Submitted: 10/10/2017 5:07:56 PM :
Start Price:
$4.02
NASDAQ:ARWR Score:
+1,549.67
Pharma companies with what are doing research with verifiable positive results in treatment for especially intractable medical conditions seem to be on a roll. I don't see this should not continue, especially as DNA/RNA research is reaching new highs at the same time.
Recs
motto1628
(62.80)
Submitted: 10/4/2015 2:59:52 AM :
Start Price:
$5.99
NASDAQ:ARWR Score:
+962.78
Functional cure for Hep B
Find the members with the highest scoring picks in ARWR.
mistermiranga (99.80) Score: +4,542.67
The Score Leader is the player with the highest score across all their picks in ARWR.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| mistermiranga | 99.80 | 12/1/2016 |
|
5Y | $1.41 | +4,687.90% | +43.06% | +4,644.85 | 0 Comment | |
| Bigsef77 | 69.72 |
|
|
3Y | $1.52 | +4,325.95% | +32.03% | +4,293.92 | 1 Comment | |
| KidJones | 34.06 | 4/22/2013 |
|
5Y | $1.78 | +3,679.21% | +102.11% | +3,577.10 | 0 Comment | |
| whoodatstockhot | 87.12 | 7/8/2013 |
|
5Y | $2.02 | +3,230.20% | +92.15% | +3,138.05 | 0 Comment | |
| EvilEmpire | 31.63 | 2/28/2013 |
|
5Y | $2.20 | +2,957.73% | +107.27% | +2,850.45 | 0 Comment | |
| MFBurritoSquat | 96.26 | 12/19/2012 |
|
3M | $2.23 | +2,916.59% | +116.35% | +2,800.24 | 0 Comment | |
| hayrettin | 70.82 | 8/24/2017 |
|
5Y | $2.50 | +2,596.19% | +28.75% | +2,567.44 | 0 Comment | |
| AJL7 | < 20 | 2/3/2016 |
|
5Y | $3.26 | +1,963.50% | +64.49% | +1,899.01 | 0 Comment | |
| beecha | < 20 | 9/19/2017 |
|
5Y | $3.35 | +1,908.06% | +25.94% | +1,882.12 | 0 Comment | |
|
Under5 | < 20 | 9/13/2017 |
|
5Y | $3.42 | +1,869.84% | +25.96% | +1,843.88 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
